{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:28:37Z","timestamp":1792052917018,"version":"4.4.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1136\/ard.2011.151043","type":"journal-article","created":{"date-parts":[[2011,7,27]],"date-time":"2011-07-27T00:26:04Z","timestamp":1311726364000},"page":"1914-1920","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":305,"title":["Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?"],"prefix":"10.1016","volume":"70","author":[{"given":"A","family":"Strangfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Eveslage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H J","family":"Bergerhausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Klopsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Zink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Listing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2011.151043_bib1","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1136\/ard.2011.151043_bib2","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1136\/ard.2008.091025","article-title":"The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events.","volume":"68","author":"Leombruno","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2011.151043_bib3","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","article-title":"Infections in patients with rheumatoid arthritis treated with biologic agents.","volume":"52","author":"Listing","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2011.151043_bib4","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","article-title":"Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2011.151043_bib5","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1002\/art.22808","article-title":"Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies.","volume":"56","author":"Dixon","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2011.151043_bib6","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.","volume":"48","author":"G\u00f3mez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2011.151043_bib7","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/ard.2006.062760","article-title":"Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists.","volume":"66","author":"Askling","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2011.151043_bib8","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/art.22504","article-title":"Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists.","volume":"56","author":"Curtis","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2011.151043_bib9","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/ard.2008.089276","article-title":"Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry.","volume":"69","author":"Greenberg","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2011.151043_bib10","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/art.21568","article-title":"Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy.","volume":"54","author":"Wolfe","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2011.151043_bib11","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/art.22600","article-title":"Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis.","volume":"56","author":"Schneeweiss","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2011.151043_bib12","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1136\/ard.2008.091926","article-title":"European biologicals registers: methodology, selected results and perspectives.","volume":"68","author":"Zink","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2011.151043_bib13","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2011.151043_bib14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2011.151043_bib15","first-page":"144","article-title":"[Comparative evaluation of a German version of the Health Assessment Questionnaire and the Hannover Functional Capacity Questionnaire].","volume":"56","author":"Lautenschl\u00e4ger","year":"1997","journal-title":"Z Rheumatol"},{"key":"10.1136\/ard.2011.151043_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/1529-0131(200002)13:1<11::AID-ART4>3.0.CO;2-5","article-title":"Loss of physical independence in rheumatoid arthritis: interview data from a representative sample of patients in rheumatologic care.","volume":"13","author":"Westhoff","year":"2000","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard.2011.151043_bib17","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2009.146","article-title":"Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.","volume":"301","author":"Strangfeld","year":"2009","journal-title":"JAMA"},{"key":"10.1136\/ard.2011.151043_bib18","doi-asserted-by":"crossref","first-page":"R66","DOI":"10.1186\/ar1933","article-title":"Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low\u2013results from RABBIT, the German biologics register.","volume":"8","author":"Listing","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard.2011.151043_bib19","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology.","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"key":"10.1136\/ard.2011.151043_bib20","series-title":"Missing Data in Clinical Studies","author":"Molenberghs","year":"2007"},{"key":"10.1136\/ard.2011.151043_bib21","first-page":"387","article-title":"The risk of hospitalized infection in patients with rheumatoid arthritis.","volume":"35","author":"Smitten","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2011.151043_bib22","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/rheumatology\/kem076","article-title":"Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis.","volume":"46","author":"Bernatsky","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2011.151043_bib23","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724190772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724190772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2011.151043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T05:31:16Z","timestamp":1737351076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724190772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0003496724190772"],"URL":"https:\/\/doi.org\/10.1136\/ard.2011.151043","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2011.151043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}